Assessment of Parkinson disease: What do we need to show neuroprotection?

Neurologist

Volumn 17, Issue 6 SUPPL., 2011, Pages

  Ybot Gorrin, Isabel ^a   Vivancos Matellano, Francisco ^a   Chacón Peña, José Rafael ^b   Alonso Navarro, Hortensia ^a   Jiménez Jiménez, Félix Javier ^a  

^a Hospital Universitario del Sureste de Madrid   (Spain)

^b Hospital Infanta Luisa   (Spain)

Author keywords

clinical evaluation; dopaminergic therapy; neuroimaging; neuroprotection; Parkinson disease; rating scales; timed tests

Indexed keywords

ALTROPANE; CEP 1347; CREATINE; DIHYDROTETRABENAZINE; DOPA DECARBOXYLASE INHIBITOR; DOPAMINE TRANSPORTER; FLUORODEOXYGLUCOSE F 18; IODINE 123; LAZABEMIDE; LEVODOPA; MINOCYCLINE; N ACETYLASPARTIC ACID; OMIGAPIL; PERGOLIDE; PLACEBO; PRAMIPEXOLE; RASAGILINE; RILUZOLE; ROPINIROLE; SELEGILINE; TOCOPHEROL; UBIDECARENONE; VESICULAR MONOAMINE TRANSPORTER 2;

ARTICLE; BRADYKINESIA; CLINICAL ASSESSMENT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DAILY LIFE ACTIVITY; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DOPAMINERGIC SYSTEM; DRUG DOSE ESCALATION; DRUG EFFECT; ENZYME ACTIVITY; FOLLOW UP; HUMAN; IN VIVO STUDY; INFLAMMATION; LIGAND BINDING; MOTOR PERFORMANCE; NERVE DEGENERATION; NEUROIMAGING; NEUROPROTECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PATIENT ASSESSMENT; PRIORITY JOURNAL; RATING SCALE; SUBSTANTIA NIGRA; TREATMENT DURATION; TREATMENT OUTCOME;

ACTIVITIES OF DAILY LIVING; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; HUMANS; NEUROIMAGING; NEUROPROTECTIVE AGENTS; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE;

EID: 80455131105     PISSN: 10747931     EISSN: None     Source Type: Journal    
DOI: 10.1097/NRL.0b013e31823966c6     Document Type: Article

References (52)

1. Shoulson I. Where do we stand on neuroprotection? Where do we go from here? Mov Disord. 1998;13(Suppl 1):46-48.
2. Hoehn MM, Yahr MD. Parkinsonism: Onset, progression and mortality. Neurology. 1967;17:427-442.
3. CAPIT Committee. Core Assessment Program for Intracerebral Transplantations (CAPIT). Mov Disord. 1992;7:2-13.
4. Lang AE, Benabid AL, Koller WC, et al. The Core Assessment Program for Intracerebral Transplantations. Mov Disord. 1995;10: 527-528.
5. Liu W, McIntire K, Kim SH, et al. Quantitative assessment of the effect of bilateral subthalamic stimulation on multiple aspects of sensorimotor function in patients with Parkinson's disease. Parkinsonism Relat Disord. 2005;11:503-508.
6. Garcia Ruiz PJ, Muñiz de Igneson J, Ayerbe J, et al. Evaluation of timed tests in advanced Parkinsonian patients who were candidates for subthalamic stimulation. Clin Neuropharmacol. 2005; 28:15-17.
7. Martínez-Martín P, García-Urra D, Balseiro-Gómez J. Timed tests in Parkinson's disease evaluation. Mov Disord. 1997;12:127-128.
8. Haaxma CA, Bloem BR, Borm GF, et al. Comparison of a timed motor test battery to the unified Parkinson's disease rating scale- III in Parkinson's disease. Mov Disord. 2008;23:1707-1717.
9. García-Ruiz PJ, Sánchez-Bernardos V, Cabo-López I. The usefulness of timed motor tests in assessing Parkinson's disease. Rev Neurol. 2009;48:617-619.
10. McLeod AD, Counsell CE. Timed test of motor function in Parkinson's disease. Parkinsonism Relat Disord. 2010;16: 442-446.
11. Jiménez-Jiménez FJ, Calleja M, Alonso-Navarro H, et al. Influence of age and gender in motor performance in healthy subjects. J Neurol Sci. 2011;302:72-80.
12. Hart RG, Pearce LA, Ravina BM, et al. Neuroprotection trials in Parkinson's disease: Systematic review. Mov Disord. 2009; 24:647-654.
13. Tetrud JW, Langston JW. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science. 1989;245: 519-522.
14. Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med. 1993;328:176-183.
15. Olanow CW, Hauser RA, Gauger L, et al. The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann Neurol. 1995;38:771-778.
16. Palhagen S, Heinonen EH, Hagglund J, et al. Selegiline delays the onset of disability in de novo parkinsonian patients. Swedish Parkinson Study Group. Neurology. 1998;51:520-525.
17. Larsen JP, Boas J, Erdal JE, Norwegian-Danish Study Group. Does selegiline modify the progression of early Parkinson's disease? Results from a five-year study. Eur J Neurol. 1999;6: 539-547.
18. Parkinson Study Group. Effect of lazabemide on the progression of disability in early Parkinson's disease. Ann Neurol. 1996;40: 99-107.
19. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med. 2004;351:2498-2508.
20. Shults CW, Oakes D, Kieburtz K, et al. Parkinson Study Group. Effects of coenzyme Q10 in early Parkinson disease: Evidence of slowing of functional decline. Arch Neurol. 2002;59: 1541-1550.
21. NINDS NET-PD Investigators. A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology. 2007;68:20-28.
22. Jankovic J, Hunter C. A double-blind, placebo-controlled and longitudinal study of riluzole in early Parkinson's disease. Parkinsonism Relat Disord. 2002;8:271-276.
23. Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol. 2004;61:561-566.
24. Olanow CW, Rascol O, Hauser R, et al. ADAGIO Study Investigators. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med. 2009;361:1268-1278.
25. Grosset K, Grosset D, Lees A, on behalf of the Parkinson's Disease Research Group of the United Kingdom. Trial of subtherapeutic pergolide in de novo Parkinson's disease. Mov Disord. 2005;20:363-366.
26. Schapira AH, Albrecht S, Barone P, et al. Rationale for delayedstart study of pramipexole in Parkinson's disease: The PROUD study. Mov Disord. 2010;25:1627-1632.
27. NINDS NET-PD Investigators. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology. 2006;66:664-671.
28. Olanow CW, Shapira AHV, LeWitt PA, et al. TCH346 as a neuroprotective drug in Parkinson's disease: A double-blind, randomized, controlled trial. Lancet Neurol. 2006;5:1013-1020.
29. Parkinson Study Group PRECEPT Investigators. Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease. Neurology. 2007;69:1480-1490.
30. Ahlskog JE, Rasagiline Uitti RJ. Parkinson neuroprotection, and delayed-start trials. Neurology. 2010;74:1143-1148.
31. Kilbourn MR, Kuszpit K, Sherman P. Rapid and differential losses of in vivo dopamine transporter and vesicular monoamine transporter radioligand binding in MPTP-treated mice. Sinapse. 2000;35:250-255.
32. Lehéricy S, Brandel JP, Hirsch EC, et al. Monoamine vesicular uptake sites in patients with Parkinson's disease and Alzheimer's disease, as measured by tritiated dihydrotetrabenazine autoradiography. Brain Res. 1994;659:1-9.
33. Frey KA, Koeppe RA, Albin RL, et al. Losses of VMAT2 in Parkinson's disease and its progression. Eur J Nucl Med. 2000; 27:927.
34. Kemmerer ES, Desmond TJ, Albin RL, et al. Treatment effects on nigrostriatal projection integrity in partial 6OH-DA lesions: comparison of L-DOPA and pramipexole. Exp Neurol. 2003;183:81-86.
35. Bezard E, Dovero S, Prunier C, et al. Relationship between the appearance of symptoms and level of nigrostriatal degeneration in a progressive 1-methyl-4phenyl-1,2,3,6-tetrahydropiridine lesioned macaque model of Parkinson's disease. J Neurosci. 2001;21:6853-6861.
36. Guttman M, Stewart D, Hussey D, et al. Influence of L-dopa and pramipexole on striatal dopamine transporter in early PD. Neurology. 2001;56:1559-1564.
37. Nurmi E, Bergman J, Eskola O, et al. Reproducibility and effect of levodopa on dopamine transporter measurements: A 18F CFT PET. J Cereb Blood Flow Metab. 2000;20:1604-1609.
38. Innis RB, Marek KL, Sheff K, et al. Effect of treatment with levodopa/carbidopa or L-selegiline on striatal dopamine transporter SPECT imaging with 123I-beta-CIT. Mov Disord. 1999;14:436-442.
39. Marek K, Innis RB, Van Dyck C, et al. 123 I-beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression. Neurology. 2001;57:2089-2094.
40. Hauser RA, Zesiewicz TA. Clinical trials aimed at detecting neuroprotection in Parkinson's disease. Neurology. 2006;66(Suppl 4):S58-S68.
41. Kieburtz K. Issues in neuroprotection clinical trials in Parkinson's disease. Neurology. 2006;66(Suppl 4):S50-S57.
42. Marek K, Innis R, van Dyck C, et al. [123I][beta]-CIT SPECT imaging assessment of the rate of Parkinson's disease progression. Neurology. 2001;57:2089-2094.
43. Pagonabarraga Mora J, Kulisevsky J. Enfermedad de Parkinson y neuroimágen funcional. In: Pagonabarraga Mora J, Kulisevsky J, eds. Enfermedad de Parkinson Enfermedad de Parkinson y neuroimagen. Barcelona: Ars Medica; 2004:25-28.
44. Le WD, Jankovic J. Are dopaminereceptor agonists neuroprotective in Parkinson's disease? Drugs Aging. 2001;18: 389-396.
45. Schapira AH. Neuroprotection and dopamine agonists (The new role of dopamine agonist in the management of Parkinsońs disease and restless legs syndrome). Neurology. 2002;58(Suppl 1): S9-S18.
46. Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REALPET study. Ann Neurol. 2003;54:93-101.
47. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA. 2002;287:1653-1661.
48. Pavese N, Kiferle L, Piccini P. Neuroprotection and imaging studies in Parkinson's disease. Parkinsonism Relat Disord. 2009; 15(Suppl):S33-S37.
49. Hernández-Vara J, Miquel-Rodríguez F. Neuroimagen de las enfermedades de los ganglios basales I: Tomografía computarizada craneal y monografía del parénquima cerebral. In: Jiménez- Jiménez FJ, Luquin MR, Molina JA, Linazasoro G, eds. Tratado de los trastornos del movimiento. Barcelona: Viguera Editores S.L.; 2008:187-201.
50. Linazasoro G, Sesar A, Valldeoriola F, et al. Neuroprotection in Parkinson's disease: Analysis though group of experts' methodology. Neurología. 2009;24:113-124. [Spanish].
51. Vaillancourt DE, Spraker MB, Prodoehl J, et al. High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease. Neurology. 2009;72:1378-1384.
52. Gómez Ansón B, Jiménez-Jiménez FJ. Neuroimagen de las enfermedades de los ganglios basales IV: Espectroscopia por resonancia magnética. In: Jiménez-Jiménez FJ, Luquin MR, Molina JA, Linazasoro G, eds. Tratado de los trastornos del movimiento. Barcelona: Viguera Editores S.L.; 2008:273-287.